Home > > > > > Report Detail

Ulcerative Colitis - Pipeline Insight, 2021

Publisher Name :
Date: 31-May-2021
No. of pages: 200
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Ulcerative Colitis - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Ulcerative Colitis Understanding

Ulcerative Colitis: Overview

Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and developes tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease.

Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool. Diarrhea is the dominant complaint in patients suffering from this disease. The patients suffer from frequent bowel movements, which may be small in volume which results to irritability of the inflamed rectum. Other symptoms of ulcerative colitis include abdominal or rectal pain, fever and weight loss. It also causes joint pain, joint swelling, skin problems and eye inflammation.

Accurate and timely diagnosis of ulcerative colitis is important to initiate appropriate treatment. The treatment of ulcerative colitis is multifaceted and includes the use of medications, alterations in diet and nutrition and some surgical procedures to repair or remove affected portions of gastrointestinal tract. Most patients with ulcerative colitis can be managed at the outpatient clinic and treated successfully. Medications such as Beclomethasone propionate and budesonide MMX, are preferred over systemic steroids owing to their superior safety profile.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The therapies under development are focused on novel approaches for Ulcerative Colitis.

Ulcerative Colitis Emerging Drugs Chapters

This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ulcerative Colitis Emerging Drugs

- Etrasimod: Arena Pharmaceuticals

Etrasimod is a next-generation, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator with an optimized S1P receptor activity profile. Etrasimod selectively targets S1P receptor subtypes 1, 4 and 5 which have been implicated in decreasing intestinal inflammation. Etrasimod does not activate S1P2 or S1P3 receptor subtypes, which are associated with cardiac, pulmonary and tumor?related side effects. Etrasimod provides systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn's disease, atopic dermatitis and alopecia areata.

It is currently in phase III stage of development for Ulcerative colitis and is being developed by Arena Pharmaceuticals.

- Upadacitinib: Abbvie

Upadacitinib (ABT-494) is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. It possess greater inhibitory potency for JAK1 versus JAK2, JAK3 and TYK2. JAK1 inhibition blocks the signaling of many important pro-inflammatory cytokines like interleukin IL-2, IL-6, IL-7, and IL-15, which are known to contribute for inflammatory disorders.

In 2019, RINVOQ (Upadacitinib) received USFDA and European Commission approval for adult patients with moderately to severely active rheumatoid arthritis who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib is currently under Phase 3 clinical studies for the treatment of atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.

Further product details are provided in the report……..

Ulcerative Colitis: Therapeutic Assessment

This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players working on Ulcerative Colitis

There are approx. 100+ key companies which are developing the Ulcerative Colitis. The companies which have their Ulcerative Colitis drug candidates in the most advanced stage, i.e. Phase III include, Arena Pharmaceuticals.

- Phases

DelveInsight's report covers around 110+ products under different phases of clinical development like

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravaginal

- Oral

- Parenteral

- Subcutaneous

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Vaccines

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ulcerative Colitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.

Ulcerative Colitis Report Insights

- Ulcerative Colitis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Ulcerative Colitis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Ulcerative Colitis drugs?

- How many Ulcerative Colitis drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for Ulcerative Colitis?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Ulcerative Colitis and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- AbbVie

- Celgene

- Eli Lilly and Company

- Lipid Therapeutics

- Hoffmann-La Roche

- Arena Pharmaceuticals

- InDex Pharmaceuticals

- EA Pharma

- FYB202 GmbH & Co KG

- Theravance Biopharma

- Boehringer Ingelheim

- Janssen Research & Development

- Lycera

- Eli Lilly and Company

- LG Chem

- Iltoo Pharma

- Immunic

- Hutchison Medipharma

- Tianjin Hemay Pharmaceutical

- GlaxoSmithKline

- Gilead Sciences

- Gossamer Bio

- Eisai

- UCB

- Suzhou Connect Biopharmaceuticals

- Landos Biopharma

- Seres Therapeutics

- Abivax

- Genentech, Inc.

- ParaTech A/S

- I-Mab Biopharma HongKong Limited

- Sublimity Therapeutics Holdco Limited|Dr. Falk Pharma GmbH

- Reistone Biopharma Company Limited

- Qu Biologics Inc.

- PurGenesis Technologies Inc.

- Protagonist Therapeutics, Inc.

- Pfizer

- Palobiofarma SL

- Novartis Pharmaceuticals

- Bristol-Myers Squibb

- Bridge Biotherapeutics

- Amgen

- Applied Molecular Transport

- AbGenomics International, Inc.

- Protalix BioTherapeutics

- LTT Bio-Pharma Co Ltd

- Dongwha pharma

- Seres Therapeutics

- Innovation Pharmaceuticals

- Holy Stone Healthcare

- SLA Pharma

- OSE Immunotherapeutics

- Bridge Biotherapeutics

- Mitsubishi Tanabe Pharma

- Sterna Biologicals GmbH

- Mesoblast

- Oncostellae

- First Wave Bio

Key Products

- Upadacitinib

- Ozanimod

- Risankizumab

- Mirikizumab

- LT-02

- Etrolizumab

- Etrasimod

- Cobitolimod

- AJM 300

- FYB 202

- TD-1473

- Spesolimab

- Guselkumab

- LYC-30937

- LY3471851

- LC51-0255

- Aldesleukin

- IMU-838

- HMPL-004

- Hemay007

- GSK2831781

- GS-4875

- GLPG3970

- GED-0301

- GB-004

- E6007

- Cimzia

- CBP-307

- BT-11

- Vancomycin

- ABX464

- UTTR1147A

- Trichuris suis ova

- TJ301

- ST-0529

- SHR0302

- QBECO SSI

- PUR 0110

- PN-943

- PF-06687234

- PF-06651600

- PF-06480605

- PBF-677

- LYS 006

- BMS-986165

- BBT-401-1S

- Apremilast

- Brazikumab

- AMT-101

- AbGn-168H

- ABBV-323

- OPRX-106

- LT 0011

- DW2007

- SER-287

- Brilacidin

- IBD98

- ALFA

- OSE-127

- BBT-401

- Amiselimod

- SB012

- Remestemcel-L

- OST-122

- Niclosamide

Ulcerative Colitis - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Ulcerative Colitis: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Ulcerative Colitis- DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Ulcerative Colitis companies' collaborations, Licensing, Acquisition -Deal Value Trends
Ulcerative Colitis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Etrasimod: Arena Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
ABBV-323: AbbVie
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
AK 101: Akeso Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
FIN-524: Finch Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix


List of Tables

Table 1 Total Products for Ulcerative Colitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for Ulcerative Colitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 110
    According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period. The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
  • Global Lansoprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 102
    The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period. The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
  • Global Esomeprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 89
    The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Irritable Bowel Syndrome (IBS) market: According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
  • Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Diarrhea Drug market: According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
  • Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
  • Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 136
    Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
  • Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 113
    Market Overview of Global Pentasa (Ulcerative Colitis) market: According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs